CNS Pharmaceuticals Inc. has announced promising scientific research results concerning their lead program, TPI 287, at the Brain Tumor Biotech Summit. TPI 287, an abeotaxane, is in development for treating glioblastoma multiforme (GBM) and has been granted Orphan Drug Designation by the FDA for treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. Unlike other taxanes that struggle to penetrate the blood-brain barrier $(BBB.UK)$, TPI 287 has shown potential in crossing the BBB to treat central nervous system tumors. In a Phase 1 trial, when used in combination with bevacizumab, TPI 287 demonstrated efficacy with 3 Complete Responses and 9 Partial Responses among 23 evaluable glioblastoma patients. These findings highlight the drug candidate's promise as a novel treatment option for brain tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.